Publications by authors named "E Veleva"
Background: Parkinson's (PD) is common and debilitating with over half of patients progressing to postural instability, dementia or death within 10 years. However, onset and rate of progression is highly variable, reflecting heterogeneity in underlying pathology, and biomarker studies to-date have been limited to a single modality or assessed patients with established cognitive impairment.
Method: We assessed multimodal neuroimaging and plasma biomarkers in 98 PD patients (mean disease duration at baseline 4.
Background: Parkinson's (PD) is common and debilitating with over half of patients progressing to postural instability, dementia or death within 10 years. However, onset and rate of progression is highly variable, reflecting heterogeneity in underlying pathology, and biomarker studies to-date have been limited to a single modality or assessed patients with established cognitive impairment.
Method: We assessed multimodal neuroimaging and plasma biomarkers in 98 PD patients (mean disease duration at baseline 4.
Article Synopsis
- Traumatic brain injury (TBI) is prevalent among military personnel and is linked to an increased risk of dementia, with the ADVANCE-TBI study focusing on the neurological effects of major battlefield trauma using blood biomarkers like NfL and GFAP.
- The study involved 1,145 servicemen and veterans, where TBI was identified in 16.9% of those exposed to major trauma, revealing significant mental health issues such as depression, anxiety, and PTSD, alongside impaired mobility and quality of life.
- Elevated GFAP levels were found post-TBI, particularly in more severe cases, indicating a correlation with mental health challenges and increased unemployment, demonstrating the long-term impact of TBI on military personnel.
Parkinson's disease is a common and debilitating neurodegenerative disorder, with over half of patients progressing to postural instability, dementia or death within 10 years of diagnosis. However, the onset and rate of progression to poor outcomes is highly variable, underpinned by heterogeneity in underlying pathological processes. Quantitative and sensitive measures predicting poor outcomes will be critical for targeted treatment, but most studies to date have been limited to a single modality or assessed patients with established cognitive impairment.
View Article and Find Full Text PDFArticle Synopsis
- * The study measured serum NfL levels in 59 gene carriers over several years and found that higher NfL concentrations correlate with more severe disease symptoms and can distinguish between presymptomatic and symptomatic individuals.
- * NfL levels not only help assess disease progression but also indicate treatment effectiveness, as levels decreased with therapy and showed a correlation with the suppression of transthyretin (TTR), a key protein involved in this condition.